Fate Therapeutics reported second quarter 2026 financial results and provided business updates. The company dosed the first patient in RECLAIM-LN, a Phase 2 potentially registrational trial for FT819 in lupus nephritis, with an expected enrollment of approximately 53 patients by the first half of 2028. FDA clearance was received for the FT839 IND application, advancing this dual CD19/CD38 CAR T-cell candidate into a Phase 1/2 basket trial for autoimmune diseases. Preliminary data for FT819 in systemic sclerosis showed positive responses with no serious adverse events reported. Financially, cash and investments decreased by $21 million to $153.8 million, supporting an operating runway into 2028. The company appointed Laura Hamill to its Board of Directors. Fate Therapeutics operates as a clinical-stage biopharmaceutical company developing iPSC-derived off-the-shelf cellular immunotherapies.

At its Annual Meeting of Stockholders held on June 12, 2026, Fate Therapeutics, Inc. stockholders approved a third amendment and restatement of the 2022 Stock Option and Incentive Plan, increasing the maximum number of shares available under the plan by 7,000,000. Additionally, shareholders elected three Class I Directors, ratified Ernst & Young LLP as the independent auditor for fiscal year 2026, and approved a non-binding advisory vote on executive compensation. A total of 87,134,422 shares were represented at the meeting. Fate Therapeutics, Inc. is a biotechnology company focused on developing cell therapies.